Navigation Links
Modular Table System: Ovation™ Orthopedic Trauma Table

ProductsModular Table System: Ovation™ Orthopedic Trauma Table
Company OSI Orthopedic Systems, Inc.
Item Modular Table System: Ovation™ Orthopedic Trauma Table
Features 
  • User-friendly positioning
  • Fast and easy setup
  • Independent leg adjustment excellent stability
  • Superior c-arm interfacing
  • Excellent stability
  • Articulating well leg support
    • Description The powered torso and leg sections of the Ovation™ Orthopedic Trauma Table simultaneously lift body and legs. Additionally, an independent lift mechanism raises and lowers legs individually and effortlessly for precise positioning. A wide range of adjustment provides the perfect position for all procedures.
    Info OSI Orthopedic Systems, Inc.
    Customer Service: (800) 777-4674
    Web site: http://www.osiosi.com

    Related medicine products :

    1. Modular Analytics
    2. Modular Pre-Analytics
    3. ADVIA IMS 800i Integrated Modular System
    4. AVL OMNI Modular System
    5. Advia WorkCell CDX Modular Automation
    6. Modular Analytics E 170 Module
    7. Bio-Modular Shoulder System
    8. Bio-Modular Total Shoulder System
    9. Modular Shoulder System*
    10. The Modular Revision Hip Stem
    11. Trabecular Metal Modular Acetabular System
    Indications For Usage: ,Used to stabilize/secure orally intubated tracheal tubes without using adhesive tapes.
    Indications For Usage: ,Facilitates intubation of tracheal tubes.
    Indications For Usage: ,Used to automatically maintain a low intracuff pressure during long-term intubations.
    Indications For Usage: ,Microlaryngeal surgery.
    Medicine Products:
    (Date:8/8/2008)...gnosis, less successful surgery, pair of studies f... -- The standard screening test for prostate cance...more vulnerable to the disease, and surgery is les...tudies found. , "Obese men are more likely to b...," said Dr. Stephen Freedland, an associate profes...
    (Date:8/8/2008)...A, Md., Aug. 8 /PRNewswire-FirstCall/ -- Hanger Or...nnounce that Moody,s Investors,Service revised its...itive",from "stable." Moody,s also affirmed Hanger...re pleased with the outlook change from Moody,s as...ten quarters," remarked George McHenry,Hanger,s C...
    (Date:8/7/2008)...ls of testosterone may be a key factor in spreadin... findings could help explain why males in a popula...ansmit disease., , Previous research has linked...tem suppression. Studies have shown that males, co...e, and account for a larger share of disease trans...
    (Date:8/7/2008)...urgh Tissue Engineering Initiative Marks 12th Year...p, PITTSBURGH, Aug. 7 /PRNewswire/ -- Twenty-four...ties, primarily across southwestern Pennsylvania,a...2th annual Summer,Internship Program of the Pittsb...l of the program is to expose greatly increased nu...
    Breaking Medicine News(10 mins):Health News:Obese Men Face Twin Threat From Prostate Cancer 2Health News:Testosterone key to disease transmission 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 3
    ...ry fibrosis (IPF) is a disease whose cause and cur...ment for it till date//. It is a lung disease char...s and slow deterioration of the entire organ (lung...000 Americans suffer from the disease and 31000 ne...
    ...und that the human form of immune-system protein, ...to make them more infectious//. Cyclophilin A is f...key cells, researchers at University College of Lo..., who infected cells from Old World monkeys with H...
    ...easingly orienting themselves to video games, high...ternational polling firm//. According to the poll...f the respondents admitted that they enjoyed video...total of 1,046 gamers, taking into consideration t...
    ... the Taiwan Laughter Club gathered in a central Ta...brate the World Laughter Day//. Led by founder Che...hanted 'Ho-Ho-Ho, Ha-Ha-Ha' several times before b...ith names like lion laugh, milkshake laugh and inn...
    Other Medicine News:Health News:Lesser Know Facts about Idiopathic Pulmonary Fibrosis (IPF) 2Health News:Taiwanese Had A Hearty Laugh On World Laughter Day 2
    (Date:8/6/2008)... Milestone achievement triggers $15 million payme...axoSmithKline, CAMBRIDGE, Mass., Aug. 6 /PRNewswi...ngaged in the discovery and development of novel,t...nced the initiation of a,pivotal Phase 3 clinical ...e new onset type 1 diabetes. As a result of the in...
    (Date:8/5/2008)... National trial aims to help heart failure patien...lot risk and less blood damage than,earlier heart ...ewswire/ -- Anthony Shannon,made history on July 3...nited States to receive a new type of experimental...DuraHeart, it was implanted in his chest, and,conn...
    (Date:8/5/2008)... CAMBRIDGE, Mass., Aug. 5 /- Tolerx,...discovery and development of novel,therapies for t...d today,that Genentech, a collaborator, has moved ... monoclonal antibody, into a phase 1 clinical tria...trial is evaluating the,safety and tolerability of...
    (Date:8/5/2008)...irst Patients Treated Using Next Generation CyberK...CyberKnife Center, SUNNYVALE, Calif., Aug. 5 /PRN...: ARAY ), a global leader in the field of radiosu...e treated using the next,generation CyberKnife(R) ...alled at the Oklahoma CyberKnife, LLC in Tulsa, OK...
    Breaking Medicine Technology:Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial 2Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial 3Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial 4First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan 2First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan 3First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan 4Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 2New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 3New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 4Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results 6259 1Boston Scientific To Webcast Conference Call Discussing Second Quarter Financial Results 6259 2American Telugu Association 26apos 3Bs Convention Attracts Over 10 000 People in the U S 6257 1American Telugu Association 26apos 3Bs Convention Attracts Over 10 000 People in the U S 6257 2American Telugu Association 26apos 3Bs Convention Attracts Over 10 000 People in the U S 6257 3American Telugu Association 26apos 3Bs Convention Attracts Over 10 000 People in the U S 6257 4Impact Systems Announces Completion of Successful Enterprise Content Migrations to Documentum 6 6255 1Impact Systems Announces Completion of Successful Enterprise Content Migrations to Documentum 6 6255 2Impact Systems Announces Completion of Successful Enterprise Content Migrations to Documentum 6 6255 3Why do people vote 3F Genetic variation in political participation 3781 1Why do people vote 3F Genetic variation in political participation 3781 2
    ...atients and physicians should find these data reas...irstCall/ --,GlaxoSmithKline said today that findi...one Evaluated for Cardiac Outcomes and,Regulation ...rial,designed specifically to determine cardiovasc...e 2 diabetes, adds further evidence to,the overall...
    ...W YORK--(BUSINESS WIRE)--Jun 5, 2007 - ERBITUX (ce...ody targeting the epidermal,growth factor receptor...stems Incorporated, was the focus of nine oral and... 43rd Annual Meeting,of the American Society of Cl...presentations showcased the extensive,clinical dev...
    Other Medicine Technology:Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 2Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 3Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 4Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 2Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 3Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 4Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 5Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 6Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 7Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 8Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 9Extensive Clinical Data on Erbitux Presented at the 2007 ASCO,Annual Meeting 10